Response by Ho et al to Letter Regarding Article, “Genotype and Lifetime Burden of Disease in Hypertrophic Cardiomyopathy: Insights From the Sarcomeric Human Cardiomyopathy Registry (SHaRe)”
Year: 2019
Type: letter
Abstract: life-saving implantable cardioverter defibrillator interventions, therapeutic hypothermia, or cardiac transplantation.[2][3][4][5] The hard truth is that HCM, like other genetic cardiomyopathies, diminishes quality of life and survival.We can only substantively change natural history by understanding the fundamental mechanisms of disease and developing disease-modifying therapies.To mistake palliation for cure is inappropriate.Much remains to be learned, and we hope that SHaRe continues to stimulate a call to action: to work collaboratively and tirelessly to target and correct the molecular abnormalities at the core of HCM, to improve the lives of our patients and families.
Source: Circulation
Institutions: Brigham and Women's Hospital, University of Michigan, Michigan Medicine, Stanford University, Erasmus MC, Universidade de São Paulo, Instituto do Coração - HCFMUSP, Yale University, NIHR Royal Brompton Cardiovascular Biomedical Research Unit, Imperial College London, Boston Children's Hospital, Howard Hughes Medical Institute, Azienda Ospedaliero-Universitaria Careggi
Language: English
Subfield: Cardiology and Cardiovascular Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W2920989901